At the intersection of endocrinology and microbiology, researchers at Cedars-Sinai Medical Center have illuminated a quiet but consequential relationship between the thyroid gland and the gut — two systems long treated as strangers. Presented at the Endocrine Society's annual conference in San Francisco, their findings suggest that an underactive thyroid more than doubles the risk of small intestinal bacterial overgrowth, while the hormone therapy already prescribed to millions appears to offer protection. In medicine, as in most human endeavors, the boundaries we draw between systems often sa
Underactive thyroid linked to doubled SIBO risk, treatable with hormone therapy
Cobertura Relacionada
Foundayo, a new daily pill treating diabetes and aiding weight loss, launches in UK pharmacies Monday. Pharmacists welco…
Mirage News · Aug 24 Study reveals type 2 diabetes in lean Africans requires different treatment approachResearch reveals type 2 diabetes in lean Africans stems from insulin deficiency, not resistance, yet they receive the sa…
Mirage News · Aug 24 Australian researchers identify existing drugs to slow rare childhood dementiaAustralian researchers identified nine existing TGA-approved medicines that could slow brain damage in children with San…
The New Indian Express · Aug 24 Odisha leads national push to prevent metabolic liver disease affecting 1 in 3 IndiansLeading gastroenterology and hepatology experts convened in Odisha to finalize national guidelines for preventing metabo…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
This is a medical research article about thyroid disease and gut health, not a geopolitical matter.
Lente Económico
Research links hypothyroidism to 2.2-2.4x higher SIBO risk, treatable with hormone therapy, potentially expanding thyroid medication market and diagnostic testing demand.
Consumers with hypothyroidism may face increased healthcare costs from additional SIBO screening and testing, but could benefit from improved treatment outcomes and reduced gastrointestinal complications through optimized thyroid hormone therapy.
Potential for updated clinical guidelines recommending SIBO screening in hypothyroidism patients; possible insurance coverage expansion for diagnostic testing; increased R&D investment in personalized microbiome-based treatments; regulatory focus on thyroid hormone therapy optimization protocols.